GSK Reports Own Share Transaction on March 24, 2026

TL;DR

**GSK is buying back its own stock, which is usually good for shareholders.**

AI Summary

GSK plc filed a 6-K on March 24, 2026, reporting a "TRANSACTION IN OWN SHARES." This filing indicates that GSK is likely repurchasing its own stock, which can reduce the number of outstanding shares and potentially boost earnings per share. For investors, this matters because share buybacks can signal management's confidence in the company's valuation and can be a way to return value to shareholders, potentially supporting the stock price.

Why It Matters

This filing signals GSK's potential share buyback activity, which can increase shareholder value by reducing outstanding shares and improving financial metrics like earnings per share.

Risk Assessment

Risk Level: low — Share buybacks are generally seen as a positive action by companies, indicating financial health and a commitment to returning value to shareholders.

Analyst Insight

A smart investor would view this as a positive signal, suggesting management believes the stock is undervalued or is committed to enhancing shareholder returns, and might consider holding or adding to their position.

Key Players & Entities

• GSK plc (company) — the filer of the 6-K
• 0001131399 (company) — GSK's CIK number
• March 24, 2026 (date) — the filing date and period of report

FAQ

Filing Documents

• a7704x.htm (6-K) — 11833KB
• 0001654954-26-002641.txt ( ) — 11835KB

From the Filing

IN OWN SHARES a7704x   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of March 2026   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .        Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 23 March 2026 Aggregate number of ordinary shares of  31¼  pence each purchased: 680,000 Lowest price paid per share (GBp): 1,906.50p Highest price paid per share (GBp): 1,964.50p Volume-weighted average price paid per share (GBp): 1,937.07p   The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 17 February 2026. Since 17 February 2026, the Company has purchased 14,011,521 ordinary shares.   Following the above purchase, the Company will hold 253,902,615 ordinary shares in treasury and have 4,062,273,663 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,062,273,663. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 6.25 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases Shares purchased:    GSK plc (ISIN: GB00BN7SWP63) Date of purchases:     23 March 2026 Investment firm:       BNP Paribas SA   Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   60,653   1,964.50p   1,906.50p   1,936.74p   CHIX   208,847   1,964.50p   1,906.50p   1,937.36p   XLON   410,500   1,964.50p   1,906.50p   1,936.96p       Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   151   1926.5   XLON   23-Mar-2026   08:00:05   20260323180876518   205   1926.5   XLON   23-Mar-2026   08:00:05   20260323180876520   189   1926.5   XLON   23-Mar-2026   08:00:05   20260323180876522   192   1926.5   XLON   23-Mar-2026   08:00:05   20260323180876524   21

View Full Filing

View this 6-K filing on SEC EDGAR